Entero Therapeutics, Inc.
ENTO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9 | $4 | $13 | $39 |
| - Cash | $0 | $4 | $1 | $8 |
| + Debt | $0 | $1 | $1 | $1 |
| Enterprise Value | $9 | $1 | $13 | $31 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$1 |
| % Margin | – | – | – | – |
| EBITDA | $0 | -$16 | -$15 | -$58 |
| % Margin | – | – | – | – |
| Net Income | -$18 | -$16 | -$15 | -$59 |
| % Margin | – | – | – | – |
| EPS Diluted | -5.26 | -46.96 | -407.37 | -27,544.98 |
| % Growth | 88.8% | 88.5% | 98.5% | – |
| Operating Cash Flow | -$9 | -$12 | -$22 | -$32 |
| Capital Expenditures | $0 | -$1 | $0 | -$10 |
| Free Cash Flow | -$9 | -$13 | -$22 | -$43 |